Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone

J Biol Chem. 2003 Jun 6;278(23):21258-66. doi: 10.1074/jbc.M302113200. Epub 2003 Mar 28.

Abstract

Fibroblast growth factor (FGF)-2 and parathyroid hormone (PTH) are potent inducers of osteoclast (OCL) formation, and PTH increases FGF-2 mRNA and protein expression in osteoblasts. To elucidate the role of endogenous FGF-2 in PTH responses, we examined PTH-induced OCL formation in bone marrow cultures from wild type and mice with a disruption of the Fgf2 gene. FGF-2-induced OCL formation was similar in marrow culture from both genotypes. In contrast, PTH-stimulated OCL formation in bone marrow cultures or co-cultures of osteoblast-spleen cells from Fgf2-/mice was significantly impaired. PTH increased RANKL mRNA expression in osteoblasts cultures from both genotypes. After 6 days of treatment, osteoprotegerin protein in cell supernatants was 40-fold higher in vehicle-treated and 30-fold higher in PTH-treated co-cultures of osteoblast and spleen cells from Fgf2-/mice compared with Fgf2+/+ mice. However, a neutralizing antibody to osteoprotegerin did not rescue reduced OCL formation in response to PTH. Injection of PTH caused hypercalcemia in Fgf2+/+ but not Fgf2-/mice. We conclude that PTH stimulates OCL formation and bone resorption in mice in part by endogenous FGF-2 synthesis by osteoblasts. Because RANKL- and interleukin-11-induced OCL formation was also reduced in bone marrow cultures from Fgf2-/mice, we further conclude that endogenous FGF-2 is necessary for maximal OCL formation by multiple bone resorbing factors.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acid Phosphatase / analysis
  • Animals
  • Antibodies / pharmacology
  • Bone Marrow Cells / cytology*
  • Carrier Proteins / genetics
  • Carrier Proteins / pharmacology
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Coculture Techniques
  • Drug Interactions
  • Fibroblast Growth Factor 2 / genetics*
  • Fibroblast Growth Factor 2 / pharmacology
  • Giant Cells / cytology
  • Glycoproteins / antagonists & inhibitors
  • Glycoproteins / genetics
  • Glycoproteins / immunology
  • Interleukin-11 / pharmacology
  • Isoenzymes / analysis
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / pharmacology
  • Mice
  • Mice, Transgenic
  • Osteoclasts / cytology*
  • Osteoclasts / enzymology
  • Osteoprotegerin
  • Parathyroid Hormone / pharmacology*
  • RANK Ligand
  • RNA, Messenger / analysis
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / immunology
  • Receptors, Tumor Necrosis Factor
  • Skull / cytology
  • Skull / drug effects
  • Spleen / cytology
  • Tartrate-Resistant Acid Phosphatase

Substances

  • Antibodies
  • Carrier Proteins
  • Glycoproteins
  • Interleukin-11
  • Isoenzymes
  • Membrane Glycoproteins
  • Osteoprotegerin
  • Parathyroid Hormone
  • RANK Ligand
  • RNA, Messenger
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Tumor Necrosis Factor
  • Tnfrsf11a protein, mouse
  • Tnfrsf11b protein, mouse
  • Tnfsf11 protein, mouse
  • Fibroblast Growth Factor 2
  • Acid Phosphatase
  • Tartrate-Resistant Acid Phosphatase